For the Inventor, By the Inventor

Enter assignee name

Maisons Alfort, France

Laboratoire L. Lafon

Calculating rank

USPTO Granted Patents = 69

% Expired Patents = 11.6

Forward Citations = 834

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Louis L Lafon (47 out of 57 patents)

Philippe Laurent (8 out of 14 patents)

Marguerite Henry (4 out of 4 patents)

4. Francis Darro (3 out of 5 patents)

5. Robert Kiss (3 out of 8 patents)

6. Armand Frydman (3 out of 4 patents)

7. Thierry Giboulot (3 out of 3 patents)

8. Christophe Yue (3 out of 3 patents)

9. Brigitte Lesur (3 out of 3 patents)

10. Gérald Guillaumet (2 out of 11 patents)

11. Benoît Joseph (2 out of 2 patents)

12. Janine Cossy (1 out of 4 patents)

13. Thanh-Tam Nguyen (1 out of 2 patents)

14. Jérôme Besse (1 out of 1 patent)

15. Tam Nguyen (1 out of 1 patent)

Core Competencies:

Pharmaceutical Composition

Radiomucositis

Chemomucositis

Quinolones

Topoisomerase II Inhibitor

Piperazinone Derivatives

Dihydropyridine Derivatives

Antidepressive Compounds

Sedative Agents

Galenic Formulations

Amino Derivatives

Therapeutic Uses

69 patents: Sort by Forward Citations

1. 7033606 - Pharmaceutical composition intended in particular for the prevention and the treatment of radiomucositis and chemomucositis (2006-04-25),

2. 6809096 - Phenanthroline-7-one derivatives and their therapeutic uses (2004-10-26),

3. 6645983 - Pharmaceutical compositions comprising 4-quinolones for treating cancers (2003-11-11),

4. 6593342 - Pharmaceutical compositions comprising 2-quinolones (2003-07-15),

5. 6562788 - Topoisomerase II inhibitor (2003-05-13),

6. 6538039 - Pharmaceutical dosage form for transdermal administration (2003-03-25),

7. 6515127 - Method for preparing quinoline-5,8-diones (2003-02-04),

8. 6344456 - Piperazinone derivatives and their uses (2002-02-05),

9. 6335337 - Substituted piperazinones and their therapeutic uses (2002-01-01),

10. 6333338 - Bispiperidines as antithrombotic agents (2001-12-25),

11. 6268397 - Use of (&agr;-aminomethyl-3,4-dichlorobenzyl) thioacetamide derivatives for inhibiting dopamine reuptake and new compounds for this use (2001-07-31),

12. 6166035 - 1,4-dihydropyridine derivatives and their use in therapy (2000-12-26),

13. 5843347 - Extrusion and freeze-drying method for preparing particles containing an (1998-12-01),

14. 5795915 - Use of (x-aminomethyl-3,4-dichlorobenzyl) thioacetamide derivatives for (1998-08-18),

15. 5719168 - Acetamide derivatives and their use as feeding behaviour modifiers (1998-02-17),

Company Overview

Laboratoire L. Lafon is a French pharmaceutical company based in Maisons Alfort, specializing in the development and manufacturing of innovative pharmaceutical compositions. The organization focuses on addressing complex medical conditions, particularly in the areas of radiomucositis and chemomucositis, utilizing advanced compounds such as quinolones and topoisomerase II inhibitors. Their research encompasses a range of therapeutic areas, including the development of piperazinone and dihydropyridine derivatives, as well as antidepressive compounds, contributing to significant advancements in patient care.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

69 Patents

#1 in Maisons Alfort

#378 in France

#10,778 in the World

Maisons Alfort, France

Laboratoire L. Lafon

Forward Citations = 834

30 inventors:

Louis L Lafon (47 out of 57 patents)

Philippe Laurent (8 out of 14 patents)

Marguerite Henry (4 out of 4 patents)

4. Francis Darro (3 out of 5 patents)

5. Robert Kiss (3 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Laboratoire L. Lafon. Retrieved from https://idiyas.com/company/laboratoire-l-lafon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…